Pharmacy First Scabies Prescribing Pathway

Under the Pharmacy First Scabies Prescribing Pathway, pharmacists manage scabies for patients aged 1 year and over through a structured framework involving screening, prescribing, contact management, and patient education

This outlines a clinical prescribing pathway for community pharmacists managing adult patients who present with recurring headaches indicative of migraines. It details a step-by-step evaluation process that includes screening for red flags, checking for medication overuse, verifying previous diagnoses, and assessing headache frequency against specific criteria. Based on these clinical evaluations, the framework guides pharmacists to either agree on an acute treatment plan, manage lifestyle habits and self-care, or issue an onward referral to general practice or emergency services when necessary. Additionally, the document provides instructions for returning patients, specifying criteria for follow-up consultations and alternative treatment adjustments. Ultimately, the pathway ensures safe and structured migraine care within a community pharmacy setting by incorporating exclusion considerations, safety-netting advice, and clear escalation routes.

Beginning in autumn 2026, NHS England introduced community pharmacy prescribing as an extension of the Pharmacy First and Pharmacy Contraception services, allowing qualified pharmacist independent prescribers to provide expanded clinical pathways and prescription management. To support this transition, healthcare professionals can access national webinars, clinical support events, and Centre for Pharmacy Postgraduate Education (CPPE) dermatology training programmes designed to enhance assessment and management skills. Comprehensive specifications and prescription management guidance establish the legal frameworks, clinical guardrails, and governance standards required for safe, high-quality patient care. Furthermore, pharmacies must complete specific onboarding processes, maintain contemporaneous electronic records, and ensure proper competencies before submitting payment claims through the NHSBSA MYS portal.

Significant updates to the Hypertension Case-Finding Service, which are scheduled to take effect in September 2026. These revisions clarify that the service is strictly for patients without a previous diagnosis and introduce new pathways for professionals like dentists and optometrists to refer individuals for monitoring. Pharmacy owners must now follow stricter protocols for off-site service delivery, including obtaining board approval and limiting such activities to four days per year. The guidance also establishes specific technical requirements for ambulatory blood pressure monitoring, such as a minimum of fourteen readings to ensure data accuracy. Furthermore, the text details administrative changes regarding staff supervision, patient follow-up procedures, and the consequences of service de-registration. Overall, these sources serve as a comprehensive operational briefing to ensure consistency and safety in how community pharmacies identify high blood pressure.

This podcast details the launch of a new Advanced service in England specifically designed to provide Meningitis B vaccinations through community pharmacies. This time-limited initiative, scheduled to run from July 2026 to March 2027, primarily targets students under 25 who are entering higher education for the first time. The program was established following significant outbreaks to protect young adults during a high-risk transitional period in shared living environments. Pharmacies must follow a strict service specification that includes using the two-dose Bexsero vaccine and recording administrations in the RAVS clinical system. To participate, providers must meet specific clinical governance standards, maintain cold chain integrity, and manage appointments through the National Booking Service. Financial incentives are offered to pharmacy owners, including a fixed fee per injection and additional bonus payments based on the volume of vaccinations delivered.

The 2026/27 funding agreement and strategic goals for the community pharmacy sector in England. A primary feature of this settlement is a 10.3% budget increase, bringing total investment to £3,636 million by merging several existing financial streams. Beyond direct funding, the deal introduces independent prescribing into core services and permits pharmacies to pause operations for four hours monthly for staff training. While the representative body accepted the offer to prevent industry collapse, they emphasize that further long-term reform and investment remain necessary to address persistent workload and financial pressures. To assist with this transition, the documents detail upcoming implementation steps, including regional roadshows and new tools for estimating pharmacy income. Finalizing this arrangement marks the beginning of a broader Community Pharmacy Strategy intended to stabilize the supply of medicines and enhance primary care.

The regulatory framework and ethical standards for the NHS Electronic Prescription Service nomination process. It emphasizes that patients hold absolute autonomy over which pharmacy or dispenser receives their prescriptions, prohibiting healthcare providers from using incentives or coercion to influence these decisions. Staff across all medical settings must ensure patients are fully informed of their right to change or remove nominations at any time without restriction. To maintain system integrity, providers are required to follow auditable procedures for obtaining consent and must reconfirm choices during significant changes, such as pharmacy ownership transfers. Finally, the guidelines establish clear accountability measures and complaint pathways to protect patient choice and ensure fair competition among dispensing contractors.

This official policy framework outlines a strategic shift in the English health system toward a neighborhood-centered model of care. By integrating NHS services with local government and social care, the initiative aims to move medical focus from hospitals to preventative, community-based environments. The document establishes specific national goals for improving GP access, managing long-term conditions like frailty and dementia, and reducing unnecessary emergency admissions. It introduces new contractual structures, such as Integrated Health Organizations, and details plans for 250 neighborhood health centers to serve as local hubs. Ultimately, the framework seeks to restore public confidence by creating a more accessible, less bureaucratic, and digitally integrated healthcare experience.

 This podcast outlines efforts by Community Pharmacy England to address and eliminate inappropriate Electronic Prescription Service (EPS) nominations and the unauthorized direction of patient services. By collaborating with NHS England and the British Medical Association, the organization is implementing stricter regulatory guidelines to ensure that medical providers do not manipulate where patients receive their medications. Key updates include a 2026/27 GP Contract amendment that requires doctors to reconfirm a patient’s chosen pharmacy when issuing new prescriptions. These measures aim to protect patient choice and prevent IT systems from automatically selecting dispensers without explicit consent. Ultimately, the initiative seeks to maintain professional integrity and transparency across the community pharmacy sector.

Starting in March 2026, the Department of Health and Social Care will implement Category H into the official Drug Tariff to reform how certain medicines are reimbursed. This new classification targets products currently in Category C that are provided by multiple manufacturers, shifting away from prices based on a single brand's list price. Instead, reimbursement rates will be determined by actual market data collected from suppliers to better reflect true pharmacy costs. While the government intends to improve the distribution of medicine margins, representative bodies like Community Pharmacy England have expressed significant concern. They argue that these imposed changes could further strain pharmacy funding and potentially destabilize an already fragile medicine supply chain.